부광약품

003000KOSPI의약품 제조업

55.4 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40

News Sentiment17.4 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 23.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Bupyeong Pharmaceutical, established in 1960, is a pharmaceutical manufacturer and distributor specializing in products like Faloba and Dexid. In 2023, it achieved a profit turnaround with consolidated sales of 160.1 billion won and operating profit of 1.6 billion won, marking a 27% sales growth year-on-year.

Number of Employees

650people

Average Salary

62.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

49.61Industry Average 14.800.0Point

3.4x industry avg (risky)

PBR

2.18Industry Average 1.040.0Point

2.1x industry avg (risky)

ROE

4.25Industry Average 4.422.5Point

Below industry avg

Debt Ratio

5.15Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲26.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲439.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.6% (improving, 3yr)

Detailed News Sentiment

10 totalPositive 7Neutral 1Negative 1Average Sentiment Score 71.7

Neutral
부광약품, 국내 최초 칼슘·비타민 등 5제 복합제 '애드타민' 출시
Negative
[유가 파장] ② 제약업계 비상…원료 확보·재고 확대 총력
중동 리스크 장기화로 유가 급등 및 원료의약품 수급 불안 우려가 커져 제약업계 전반에 공급망 안정과 비용 절감 노력이 필요하다.
Positive
“부광약품, 2030년 매출 20위 진입”
부광약품이 창사 이래 최초로 매출 2000억원 시대를 열고 2030년까지 국내 제약업계 매출 상위 20위권 진입을 목표로 하는 중장기 비전을 발표했으며, 파격적인 배당 정책으로 주가가 17% 이상 급등했습니다.

Detailed Momentum

52-week position6.0Point

52w upper range (67%)

Current 7,540Won52-week high 9,60052-week low 3,225

1-month return6.0Point

1m +23.81% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral정기주주총회결과2026-03-24
Neutral기업가치제고계획(자율공시)2026-03-24
Neutral사업보고서 (2025.12)2026-03-16
Neutral감사보고서제출2026-03-16